Cerebrolysin vs ARA-290
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: FPE 1070
A mixture of low-molecular-weight neuropeptides derived from pig brain. Approved in many countries for stroke, traumatic brain injury, and dementia.
Also: Cibinetide, ARA 290
An 11-amino acid peptide derived from erythropoietin (EPO) that activates the innate repair receptor. Unlike EPO, it has no erythropoietic activity but provides cytoprotective, anti-inflammatory, and tissue-protective effects.
Key Comparison Insights
- Both peptides belong to the Cognitive category, suggesting similar primary applications.
Detailed Comparison
| Attribute | Cerebrolysin | ARA-290 |
|---|---|---|
| Category | Cognitive | Cognitive |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Cerebrolysin contains neurotrophic factors that mimic BDNF, NGF, and CNTF activity. It enhances neuroplasticity, protects neurons from excitotoxicity, promotes neurogenesis, and improves synaptic function. | ARA-290 selectively activates the innate repair receptor (IRR), a heterodimer of EPOR and CD131 (β common receptor). This receptor is expressed on damaged and inflamed tissues. Activation triggers anti-apoptotic, anti-inflammatory, and tissue-protective pathways without stimulating red blood cell production. |
| Common Dosing | 5-10 ml IV/IM daily for 10-20 days Daily during treatment cycles | 4 mg daily Once daily |
| Administration | Intravenous or intramuscular injection | Subcutaneous injection |
| Typical Duration | 10-20 day cycles | 28-day courses in trials |
| Best Time to Take | Morning | Consistent daily timing |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Approved in over 40 countries for neurological conditions. Studies show benefits in stroke recovery, Alzheimer's disease, and TBI. Large clinical trials demonstrate improved cognitive function and activities of daily living. | Phase II/III clinical trials for diabetic neuropathy show improvement in corneal nerve fiber density and small fiber function. Orphan Drug Designation granted in both US and EU for sarcoidosis treatment. Studies demonstrate efficacy in small fiber neuropathy, neuropathic pain, and sarcoidosis-related symptoms. Being developed by Araim Pharmaceuticals. |
Frequently Asked Questions: Cerebrolysin vs ARA-290
What is the difference between Cerebrolysin and ARA-290?
Cerebrolysin is a cognitive peptide that a mixture of low-molecular-weight neuropeptides derived from pig brain. approved in many countries for stroke, traumatic brain injury, and dementia. ARA-290 is a cognitive peptide that an 11-amino acid peptide derived from erythropoietin (epo) that activates the innate repair receptor. unlike epo, it has no erythropoietic activity but provides cytoprotective, anti-inflammatory, and tissue-protective effects. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Cerebrolysin or ARA-290?
Neither is universally "better" - the choice depends on your specific goals. Cerebrolysin is typically used for cognitive purposes, while ARA-290 is used for cognitive. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Cerebrolysin and ARA-290 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Cerebrolysin and ARA-290 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.
Related Comparisons
View Full Peptide Profiles
Educational Information Only
This comparison of Cerebrolysin and ARA-290 is for educational purposes only. Neither this comparison nor any information on this site constitutes medical advice. Always consult with qualified healthcare providers before making decisions about peptides or other substances.